Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

Summary

Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the investigational agent for this penile cancer study.

Timeline

Start

2016-10

Primary completion

2019-10

Completion

2019-10

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Drugs

Indications